These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 19786600)

  • 21. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole.
    Martinez M; López-Ribot JL; Kirkpatrick WR; Coco BJ; Bachmann SP; Patterson TF
    J Clin Microbiol; 2002 Sep; 40(9):3135-9. PubMed ID: 12202543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-candidal activity of selected analgesic drugs used alone and in combination with fluconazole, itraconazole, voriconazole, posaconazole and isavuconazole.
    Król J; Nawrot U; Bartoszewicz M
    J Mycol Med; 2018 Jun; 28(2):327-331. PubMed ID: 29605543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel.
    Samra Z; Yardeni M; Peled N; Bishara J
    Eur J Clin Microbiol Infect Dis; 2005 Sep; 24(9):592-5. PubMed ID: 16172856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [In vitro activities of posaconazole, fluconazole, itraconazole, ketoconazole and voriconazole against Candida glabrata].
    Blanco MT; Cañadas J; García-Martos P; Marín P; García-Tapia A; Rodríguez J
    Rev Esp Quimioter; 2009 Sep; 22(3):139-43. PubMed ID: 19662547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antifungal susceptibility of 50 Candida isolates from invasive mycoses in Chile.
    Silva V; Alvarado D; Diaz MC
    Med Mycol; 2004 Jun; 42(3):283-5. PubMed ID: 15283244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Voriconazole and fluconazole susceptibility of Candida isolates.
    Pelletier R; Loranger L; Marcotte H; DE Carolis E
    J Med Microbiol; 2002 Jun; 51(6):479-483. PubMed ID: 12018654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluconazole resistant opportunistic oro-pharyngeal Candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria.
    Enwuru CA; Ogunledun A; Idika N; Enwuru NV; Ogbonna F; Aniedobe M; Adeiga A
    Afr Health Sci; 2008 Sep; 8(3):142-8. PubMed ID: 19357740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency of clinically isolated strains of oral Candida species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006-2007 and 2012-2013.
    Kamikawa Y; Mori Y; Nagayama T; Fujisaki J; Hirabayashi D; Sakamoto R; Hamada T; Sugihara K
    BMC Oral Health; 2014 Feb; 14():14. PubMed ID: 24552136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro susceptibility of oral Candida to seven antifungal agents.
    Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
    Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Fluconazole-resistant Candida species from HIV infected patients with recurrent Candida stomatitis: cross resistance to itraconazole and ketoconazole].
    Metzger S; Hofmann H
    Mycoses; 1997; 40 Suppl 1():56-63. PubMed ID: 9417515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emergence of non-Candida albicans species: Epidemiology, phylogeny and fluconazole susceptibility profile.
    Sadeghi G; Ebrahimi-Rad M; Mousavi SF; Shams-Ghahfarokhi M; Razzaghi-Abyaneh M
    J Mycol Med; 2018 Mar; 28(1):51-58. PubMed ID: 29366545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular typing and in vitro fluconazole susceptibility of Candida species isolated from diabetic and nondiabetic women with vulvovaginal candidiasis in India.
    Lattif AA; Mukhopadhyay G; Banerjee U; Goswami R; Prasad R
    J Microbiol Immunol Infect; 2011 Jun; 44(3):166-71. PubMed ID: 21524609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea.
    Lee JS; Shin JH; Lee K; Kim MN; Shin BM; Uh Y; Lee WG; Lee HS; Chang CL; Kim SH; Shin MG; Suh SP; Ryang DW
    Yonsei Med J; 2007 Oct; 48(5):779-86. PubMed ID: 17963334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: species identification and antifungal susceptibility of Candida isolates.
    Waikhom SD; Afeke I; Kwawu GS; Mbroh HK; Osei GY; Louis B; Deku JG; Kasu ES; Mensah P; Agede CY; Dodoo C; Asiamah EA; Tampuori J; Korbuvi J; Opintan JA
    BMC Pregnancy Childbirth; 2020 May; 20(1):266. PubMed ID: 32375724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? The National Institute of Allergy and Infectious Diseases Mycoses study group.
    Goldman M; Cloud GA; Smedema M; LeMonte A; Connolly P; McKinsey DS; Kauffman CA; Moskovitz B; Wheat LJ
    Antimicrob Agents Chemother; 2000 Jun; 44(6):1585-7. PubMed ID: 10817713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross-resistance to triazole antifungal agents.
    Chen TC; Chen YH; Chen YC; Lu PL
    Kaohsiung J Med Sci; 2012 Jun; 28(6):306-15. PubMed ID: 22632885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in
    Espinel-Ingroff A; Turnidge J; Alastruey-Izquierdo A; Botterel F; Canton E; Castro C; Chen YC; Chen Y; Chryssanthou E; Dannaoui E; Garcia-Effron G; Gonzalez GM; Govender NP; Guinea J; Kidd S; Lackner M; Lass-Flörl C; Linares-Sicilia MJ; López-Soria L; Magobo R; Pelaez T; Quindós G; Rodriguez-Iglesia MA; Ruiz MA; Sánchez-Reus F; Sanguinetti M; Shields R; Szweda P; Tortorano A; Wengenack NL; Bramati S; Cavanna C; DeLuca C; Gelmi M; Grancini A; Lombardi G; Meletiadis J; Negri CE; Passera M; Peman J; Prigitano A; Sala E; Tejada M
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidemiology and antifungal susceptibility testing of non-albicansCandida species colonizing mucosae of HIV-infected patients in Yaoundé (Cameroon).
    Ngouana TK; Toghueo RMK; Kenfack IF; Lachaud L; Nana AK; Tadjou L; Kouanfack C; Boyom FF; Bertout S
    J Mycol Med; 2019 Sep; 29(3):233-238. PubMed ID: 31204235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia?
    Kovacicova G; Krupova Y; Lovaszova M; Roidova A; Trupl J; Liskova A; Hanzen J; Milosovic P; Lamosova M; Macekova L; Szovenyiova Z; Purgelova A; Obertik T; Bille J; Krcmery V
    J Infect Chemother; 2000 Dec; 6(4):216-21. PubMed ID: 11810569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterologous Expression of Full-Length Lanosterol 14α-Demethylases of Prominent Fungal Pathogens Candida albicans and Candida glabrata Provides Tools for Antifungal Discovery.
    Keniya MV; Ruma YN; Tyndall JDA; Monk BC
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.